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A B S T R A C T   
Background: Physiotherapy is used as a non-pharmacological treatment for migraine. However, controversy exists 
over whether articulatory manual techniques are effective in some aspects related to migraine. 
Objectives: To assess the effectiveness of a manual therapy protocol based on articulatory techniques in pain 
intensity, frequency of episodes, migraine disability, quality of life, medication intake and self-reported 
perceived change after treatment in migraine patients. 
Design: Randomized controlled trial. 
Methods: Fifty individuals with migraine were randomized into the experimental group, which received manual 
therapy based on articulatory techniques (n = 25), or the placebo group (n = 25). The intervention lasted 4 
weeks and included 4 sessions. Patients were assessed before (T1), after (T2) and at a one-month follow-up 
following the intervention (T3). The instruments used were the Migraine Disability Assessment (MIDAS) ques-
tionnaire, the Short Form-36 Health Survey (SF-36), the medication intake and The Patients’ Global Impression 
of Change scale. 
Results: In comparison with placebo group, manual therapy patients reported significant effects on pain intensity 
at T2 (p < 0.001; d = 1.15) and at T3 (p < 0.001; d = 1.13), migraine disability at T3 (p < 0.05; d = 0.69), 
physical quality of life at T2 (p < 0.05; d = 0.72), overall quality of life at T2 (p < 0.05; d = 0.60), decrease in 
medication intake at T2 (p < 0.001; d = 1.11) and at T3 (p < 0.05; d = 0.77) and self-reported perceived change 
after treatment at T2 and T3 (p < 0.001). No serious adverse events were reported. 
Conclusions: The application of a manual therapy protocol based on articulatory techniques reduced pain in-
tensity, migraine disability, and medication intake, while improving quality of life in patients with migraine.   
3. Introduction 
Migraine is a primary headache that affects one in ten people 
worldwide with an upward trend (Woldeamanuel and Cowan, 2017), 
and is the leading cause of disability in the 15-49-year-old age group 
(Steiner et al., 2018; GBD 2016, 2017). Migraine has a significant in-
dividual impact on productivity, thus favoring both work and school 
absenteeism (Baigi and Stewart, 2015), not only due to the limitations 
associated with migraine symptoms, but also because of the possible side 
effects of the drugs used (Vicente-Herrero et al., 2013). As a result, 
migraine has a major impact on the patient’s quality of life (QoL), and 
may become a public health problem with personal, work and economic 
implications (Leonardi and Raggi, 2019). 
The most common treatment option is pharmacological, however, 
medication is sometimes ineffective or involves side effects (Becker 
et al., 2015; Capi et al., 2018). Indeed, excessive intake of medication is 
considered as a risk factor for chronic migraine (Xu et al., 2020; 
Schwedt, 2014). Therefore, non-pharmacological treatment may be a 
good option for some patients, considering that a number of processes 
such as stress (Pellegrino et al., 2018; Kelman, 2007), certain psychiatric 
comorbidities (Dresler et al., 2019) and musculoskeletal dysfunctions 
(Palacios-Ceña et al., 2017; Ferracini et al., 2017; Nahman-Averbuch 
et al., 2018; Szikszay et al., 2019) can contribute to the development of 
migraine, increase disability (Steiner et al., 2018; GBD 2016, 2017) and 
adversely affect quality of life (Abu Bakar et al., 2016). 
Manual therapy may reduce pain intensity, frequency and duration 
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of migraine episodes (Luedtke et al., 2016; Chaibi et al., 2011; Grant and 
Niere, 2000). In this regard, it has been proposed that articulatory 
techniques (i.e., those in which low velocity and moderate to high 
amplitude movements are employed to force joint’s full range of motion) 
can contribute to improving the possible limitations of the range of 
motion of the affected joints and trigger systemic neurophysiological 
responses that lead to pain inhibition (Bialosky et al., 2009, 2018; 
Schmid et al., 2008; Voogt et al., 2015). Thus, it has been suggested that 
joint mobilization may reduce the intensity of pain (Gandolfi et al., 
2018; Davidson et al., 2018; Chaibi et al., 2017) and the frequency of 
migraine (Davidson et al., 2018; Chaibi et al., 2017) up to six months 
after the intervention (Davidson et al., 2018; Chaibi et al., 2017), 
although given the variability in the quality of previous studies it is 
difficult to determine the magnitude of this effect (Rist et al., 2019). 
Furthermore, controversy exists over whether it is effective in 
migraine-associated disability compared to placebo interventions (Rist 
et al., 2019). A number of studies that have applied articulatory tech-
niques combined with soft-tissue techniques have reported improve-
ments in impact and functional disability after 24 weeks of intervention 
in patients with chronic migraine (Cerritelli et al., 2015), as well as 
on-the-job and household-associated disability after 10 weeks of inter-
vention in patients with episodic migraine (Voigt et al., 2011); in 
contrast, others have achieved no significant effect on 
migraine-associated disability after four weeks of intervention and 
onabotulinum toxin A injection in patients with chronic migraine 
(Gandolfi et al., 2018). In addition, the effect of a treatment exclusively 
using articulatory spinal techniques has shown its effectiveness in 
disability and QoL associated with other primary headaches (Espí-López 
et al., 2014; Monzani et al., 2016). However, subjective perception of 
change after treatment in individuals with migraine has not been 
investigated to date. 
The aim of this study was to compare the effectiveness of a manual 
therapy protocol based on articulatory techniques with a hands-on 
placebo intervention in pain intensity, frequency of episodes, migraine 
disability, physical, mental and overall QoL, medication intake and self- 
reported perceived change after treatment in individuals with migraine. 
We further aimed to assess whether the effects were maintained one 
month after the intervention. 
4. Materials and methods 
4.1. Participants 
Fifty individuals diagnosed with migraine were recruited as a con-
venience sample from several primary care centers in Valencia (Spain) 
from June to July 2018. Individuals between 18 and 50 years of age 
diagnosed according the ICHD-3 criteria (Headache Classification 
Committee of the International Headache Society (IHS), 2018), with 
four or more episodes per month, and a migraine history of one or more 
years were included in the study; headache medication regimens should 
be stabilized for four weeks prior to enrolment. Exclusion criteria were: 
(i) patients with another type of primary or secondary headache, (ii) 
temporomandibular disorders, (iii) signs of vertebral artery or internal 
carotid artery commitment, (iv) spinal radiculopathy, (v) vertigo, (vi) 
decompensated blood pressure, (vii) pregnancy, or (vii) in the process of 
pharmacological adaptation. Participants could use symptomatic 
medication when required (Diener et al., 2019). 
4.2. Study design 
A randomized controlled trial was carried out (NCT03555214), from 
June to October 2018 at the University of Valencia. The sample was 
randomly divided into 2 groups: a) Articulatory group (AG) (n = 25), 
that received a manual therapy protocol based on articulatory tech-
niques; and b) Placebo group (PG) (n = 25), who received a hands-on 
placebo intervention. Both treatments lasted 4 weeks and included 4 
sessions (one per week). Patients were assessed before (T1), immedi-
ately after (T2), and at one-month follow-up after the intervention (T3). 
All participants provided written informed consent, all procedures 
were conducted in accordance with the ethical standards of the Decla-
ration of Helsinki and the protocols were approved by the Ethics Com-
mittee of the University of Valencia (H1509655117217). 
4.2.1. Randomization, blinding and masking 
An external investigator who was not involved in the assessment or 
treatment of the participants performed the randomized allocation by 
preparing sealed, sequentially numbered envelopes that contained the 
treatment assignments. The physiotherapist opened the lowest 
numbered envelope to reveal the patient’s assignment just before the 
treatment was performed. Patients and statistician were blinded to the 
treatment allocation. 
4.3. Interventions 
All the participants underwent a careful clinical history (Chaibi and 
Russell, 2019) and pre-manipulative testing of the cervical spine (Côté 
et al., 1996) performed by the physiotherapist, to detect (and thus 
exclude) any possible cervical artery dissection. No participant was 
excluded due to this reason. All techniques were executed by the same 
experienced physiotherapist, who had over 7 years’ experience in the 
application of manual therapy for headache patients and had received 
more than 5 years of postgraduate training. During each session, po-
tential adverse effects or harms were recorded. 
AG participants were applied all the defined articulatory techniques 
in all the potential restricted joints related to migraine (Chaibi et al., 
2017). For that purpose, low velocity and moderate to high amplitude 
movements were conducted on the neck and upper-trunk joints and 
sacroiliac joints to force their full range of motion. Specifically, the 
following techniques were applied bilaterally in all treatment sessions 
(Dunning et al., 2016): occiput-atlas-axis articulatory manipulation, 
upper cervical spine (C0–C1) mobilization, middle cervical spine 
(C2–C7) mobilization in supine, middle cervical spine (C2–C7) mobili-
zation in prone, cervicothoracic junction articulatory manipulation, 
upper thoracic spine (T2-T6) articulatory manipulation and global 
sacroiliac joint articulatory manipulation. These techniques are 
described in detail in Appendix A. 
Regarding the PG, the physiotherapist performed a superficial hands- 
on placebo intervention by gently placing the palms of both hand under 
the occiput for 10 min. No force or movement was applied (Cardoso--
de-Mello-E-Mello-Ribeiro et al., 2015). 
4.4. Main outcome measures 
Migraine disability was assessed by the Migraine Disability Assess-
ment (MIDAS) questionnaire (Stewart et al., 1999), which is based on 
five questions about the number of days lost due to headaches in the last 
three months. Additionally, this questionnaire includes two questions 
related to pain intensity and frequency of the episodes. The 
between-group minimally important difference is a 5-point decrease 
(Buse et al., 2018). It is considered a valid (α de Cronbach = 0.73–0.76) 
and reliable instrument (r = 0.80). (Stewart et al., 2001). 
Physical, mental, and overall QoL was assessed with the Short Form-36 
Health Survey (SF-36) (Ware and Sherbourne, 1992), a 36-item instru-
ment that assesses health-related QoL. The physical component of the 
SF-36 evaluates physical functioning, physical role functioning, bodily 
pain and general health perceptions, whereas its mental component 
assesses vitality, social role functioning, emotional role functioning and 
mental health. For each dimension, the items are given a code number, 
aggregated and transformed into a scale ranging from 0 to 100, with 
higher values indicating better health (Vilagut et al., 2005). Effects 
larger than 12% of baseline score can be detected as minimal clinically 
important difference (Perrot and Lantéri-Minet, 2019). The 
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questionnaire has shown to have good validity (Cronbach’s α =
0.70–0.90) and reliability (ICC = 0.58–0.99). (Vilagut et al., 2005). 
The amount of symptomatic medication was registered in a stan-
dardized migraine dairy, as number of pills per day (Gandolfi et al., 
2018). The percentage of medication intake reduction was further 
calculated both at T2 and at T3. 
Self-reported perceived change after treatment was assessed with the 
Patients’ Global Impression of Change (PGIC) scale, which consists of a 
7-point verbal scale, with the options “very much improved”, “much 
improved”, “minimally improved”, “no change”, “minimally worse”, 
“much worse”, “very much worse” (Angst et al., 2001; Dworkin et al., 
2008). Clinically significant improvement is considered to be achieved 
when items “much improved” and “very much improved” are rated 
(Angst et al., 2001; Dworkin et al., 2008). The test-retest reliability of 
the global rating of change scales has been shown to be excellent (ICC =
0.90) (Kamper et al., 1999). This variable was recorded at T2 and T3. 
4.5. Statistics 
Statistical analyses were performed using SPSS v.24 (IBM SPSS, Inc., 
Chicago, IL, USA). The inferential analyses of the data were conducted 
using a two-factor mixed multivariate analysis of variance (MANOVA) 
having a between-subjects factor “treatment group” with two categories 
(AG and PG) and a within-subject factor “time measurements” with 
three categories (T1, T2 and T3) for all the variables except for medi-
cation intake, for which the mixed MANOVA included only two cate-
gories in the within-subject factor (T2 and T3). Post-hoc analyses were 
requested using the Bonferroni correction. We evaluated the assumption 
of homoscedasticity using Levene’s test and the sphericity using 
Mauchly’s test. A Chi-squared test was used to explore the relationship 
between the intervention (AG and PG) and the self-reported perceived 
change at each time measurement (T2 and T3). Additionally, we 
explored similarity between groups at baseline using the Independent 
Student’s t-test for the continuous variables and a Chi-squared test for 
the categorical variables. The α level was set equal to or less than 0.05 
for all tests. For the effect size of the continuous variables, Cohen’s d was 
computed, whereby the effect size was rated as follows: small 
(0.20–0.50), medium (0.50–0.80), or large (>0.80) (Thalheimer and 
Cook, 2002). For the categorical variables, the effect size was reported 
with the contingency coefficient (CC). 
4.5.1. Sample size calculation 
For computing sample size, we considered that our study was 
composed of two groups and three measurements, and we set a power of 
80% and an effect size of (d = 0.88) based on a previous study conducted 
by Espí-López et al. (2018), in which a similar approach was proposed. 
This generated a minimum sample size of 12 participants per group (a 
total of 24 participants). Nevertheless, we doubled the recruitment 
taking into consideration possible dropouts (i.e., 50 participants). 
5. Results 
5.1. Participants 
Fifty participants were randomly allocated to the AG and the PG (25 
participants in each group) and all of them completed the study (Fig. 1). 
The mean (standard deviation, SD) age of the participants was 38.5 (9.6) 
years. There were no significant differences between groups before the 
intervention in any variable (Table 1). No serious intervention-related 
side effects occurred. 
Fig. 1. Flowchart according to CONSORT Statement for the Report of randomized trials.  
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5.2. General multivariate analysis results 
MANOVA analysis showed a statistically significant interaction be-
tween factors “treatment groups” (AG and PG) and “time measure-
ments” (T1, T2 and T3), Pillai’s trace Ѵ = 0.8, F (22, 27) = 3.7, p =
0.001, ƞ2 = 0.8. 
5.3. Effect of the treatment on intensity, frequency of the episodes, and 
migraine disability 
There was a significant interaction between the two factors (i.e., 
treatment groups and time measurements) in pain intensity F (2, 96) =
12.2, p < 0.001, η2p = 0.2, frequency of the episodes F (1.2, 58.3) =
13.3, p < 0.001, η2p = 0.2, and migraine disability F (1.1, 52.8) = 32.9, 
p < 0.001, η2p = 0.4. 
There were significant intra-group mean differences [95% confi-
dence interval] in AG in pain intensity, with a large effect size, at T1-T2 
(1.0 [0.6 to 1.4]) and at T1-T3 (0.9 [0.5 to 1.3]); in frequency of the 
episodes, with a small size effect, at T1-T2 (2.8 [1.7 to 4.0]) and T1-T3 
(4.2 [2.6 to 5.8]); and in migraine disability, with a small-medium effect 
size, at T1-T2 (4.5 [3.0 to 5.9]) and T1-T3 (10.4 [7.2 to 13.5]). There 
were no significant intra-group differences in PG in any of the variables 
(p ≥ 0.05). 
In addition, the post hoc analysis revealed significant inter-group 
mean differences [95% CI] between AG and PG in pain intensity, with 
a large effect size at T2 (1.2 [0.6 to 1.9]) and at T3 (1.1 [0.6 to 1.7]); and 
in migraine disability, with a medium effect size at T3 (10.0 [1.8 to 
18.2]). Table 2 shows the results of pairwise comparisons when the ef-
fect of the treatment was analyzed in each group. 
5.4. Effect of the treatment on quality of life 
There was a significant interaction between the two factors (i.e., 
treatment groups and time measurements) in Physical QoL F (2, 96) =
3.2, p < 0.05, η2p = 0.1, and Overall QoL F (2, 96) = 3.8, p < 0.05, η2p =
0.1; but not in Mental QoL (p ≥ 0.05). 
As noted in Table 2, there were significant intra-group mean differ-
ences [95%CI] in AG in the scores for the variable Physical QoL at T1-T2 
(− 14.5 [-23.8 to − 5.1]) and T1-T3 (− 14.4 [-22.4 to − 6.4]); Mental QoL 
at T1-T2 (− 14.4 [-22.7 to − 6.1]) and T1-T3 (− 13.3 [-21.5 to − 5.0]); 
Overall QoL at T1-T2 (− 14.4 [-22.1 to − 6.8]) and T1-T3 (− 13.8 [-20.8 
to − 6.9]). Table 3 shows the results for SF-36 sub-scales. There were no 
significant intra-group differences in PG in any of the SF-36 question-
naire scores. 
Regarding the differences between groups, there were significant 
inter-group mean differences [95% CI] in AG in the scores for the var-
iables Physical QoL (− 11.9 [-21.6 to − 2.2]) and Overall QoL (− 9.3 
Table 1 
Baseline demographic and headache characteristics.  
Variables PG (n = 25) AG (n = 25) p-value 
Gendera   0.73 
Female 20 (80) 19 (76)  
Male 5 (20) 6 (24)  
Migraine diagnosea   0.77 
Episodic migraine 14 (56) 15 (60)  
Chronic migraine 11 (44) 10 (40)  
Family historya 17 (68) 18 (72) 0.76 
Medicationa   0.89 
Preventive medication 2 (8) 3 (12)  
Symptomatic medication 22 (88) 21 (84)  
No medication 1 (4) 1 (4)  
Accompanying symptomsa    
Nausea/Vomiting 16 (64) 11 (44) 0.16 
Aura 6 (24) 5 (20) 0.73 
Photophobia 15 (60) 15 (60) 1.00 
Phonophobia 10 (40) 12 (48) 0.57 
Ageb 37.6 (9.42) 39.1 (9.9) 0.95 
Age of onsetb 20.0 (10.7) 21.2 (10.3) 0.76 
Period of evolution (years)b 17.7 (9.9) 17.9 (10.6) 0.57 
Duration of the episodes (hours)b 22.2 (14.7) 23.2 (20.3) 0.08 
Painb 7.7 (1.0) 7.45 (1.3) 0.17  
a Data shown as Absolute frequency (% relative frequency). 
b Data shown as Mean (Standard deviation). PG: Placebo Group; AG: Articu-
latory Group. 
Table 2 
Effect of the treatment on MIDAS and SF-36 scores (main variables) by time and group.    
Mean (Standard deviation) Measurement times comparison 
Mean Difference (95%CI); Effect size (Cohen’s d) 
Groups comparison 
Mean Difference (95%CI); Effect size (Cohen’s 
d) 




T1-T2 T1-T3 T2 (week 4) T3 (Week 8) 
Intensity (MIDAS) PG 7.6 (0.8) 7.9 (1.1) 7.6 (0.9) − 0.1 (− 0.5 to 0.3) − 0.02 (− 0.4 to 0.4) 1.2 (0.6–1.9)***; d =
1.2 
1.1 (0.6–1.7)***; d 
= 1.1 AG 7.4 (1.1) 6.4 (1.0) 6.5 (1.0) 1.0 (0.6–1.4)***; d =
0.9 
0.9 (0.5–1.3)***; d = 0.8 















2.8 (1.7–4.0)***; d =
0.3 

















4.5 (3.0–5.9)***; d =
0.2 
10.4 (7.2–13.5)***; d =
0.6 






− 2.4 (− 11.8 to 6.9) − 3.4 (− 11.4 to 4.6) − 11.9 (− 21.6 to 
− 2.2)*; d = 0.7 








− 14.5 (− 23.8 to 
− 5.1)**; d = 0.9 
− 14.4 (− 22.4 to 
− 6.4)***; d = 0.7 













− 14.4 (− 22.7 to 
− 6.1)***; d = 0.7 
− 13.3 (− 21.5 to 
− 5.0)**; d = 0.5 






− 3.5 (− 11.1 to 4.1) − 4.1 (− 11.0 to 2.8) − 9.3 (− 18.0 to − 0.5)*; 
d = 0.6 







− 14.4 (− 22.1 to 
− 6.8)***; d = 0.8 
− 13.8 (− 20.8 to 
− 6.9)***; d = 0.7 
CI indicates confidence interval; PG: placebo control group; AG: articulatory group. MIDAS: Migraine Disability Assessment. QoL: Quality of Life. T1: Pre-treatment; 
T2: Post-treatment: T3: Follow-up; *: p < 0.05; **: p < 0.01; ***: p < 0.001; d: Cohen’s effect size (only for the significant comparisons). 
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[-18.0 to − 0.5]) at T2, with a medium effect size. 5.4.1. Effect of the treatment on medication intake 
Fig. 2 shows that the percentage of decrease in medication intake 
was greater in the AG (42.5%) than in the PG (14.5%) at T2 t (46) = 3.9, 
p < 0.001, d = 1.1, with a large effect size, and at T3 (34.4% and 12.1%, 
respectively) t (46) = 2.7, p < 0.05, d = 0.8, with a moderate effect size. 
There were no differences between T2 compared to T3 in either group 
(p ≥ 0.05). 
5.5. Perceived change after treatment 
There was a significant relationship between the scale categories and 
the groups at both T2, χ2 (Steiner et al., 2018)(4) = 18.7, p = 0.001, CC 
= 0.5, and T3, χ (Steiner et al., 2018)(3) = 24.5, p < 0.001, CC = 0.6. 
There were no differences between T2 compared to T3 in either group 
(p ≥ 0.05). As shown in Fig. 3A, at T2, 60% of the PG felt no change, 
while 84% of the AG felt minimally or much improved. At T3 (Figs. 3B), 
80% of the PG felt no change, while 76% of the AG felt minimally or 
much improved. 
6. Discussion 
The present protocol based on articulatory techniques was effective 
in reducing pain intensity, migraine disability and medication intake, 
while improving physical QoL and self-reported perceived change after 
treatment; these changes were maintained after one month. Further-
more, significant differences were observed in terms of frequency of 
episodes and mental QoL at T2 and T3 compared to the placebo inter-
vention. To date, to the best of our knowledge, this is the first study to 
evaluate the therapeutic effect of articulatory techniques on QoL and 
Table 3 
Effect of the treatment on the SF-36 scores (sub-dimensions) by time and group.    
Mean (Standard deviation) Measurement times comparison 
Mean Difference (95%CI); Effect size (Cohen’s d) 
Groups comparison 
Mean Difference (95%CI); Effect size (Cohen’s d) 





























− 4.0 (− 24.1 to 16.1) − 4.6 (− 25.6 to 16.4) − 22.1 (− 40.4 to 
− 3.8)*; d = 0.7 
− 24.5 (− 46.2 to 







− 26.0 (− 46.1 to 
− 5.9)**; d = 1.0 
− 29.0 (− 50.0 to 
− 8.1)**; d = 0.9 






− 0.1 (− 14.1 to 13.9) − 1.0 (− 11.5 to 9.5) − 13.6 (− 23.9 to 
− 3.3)**; d = 0.8 







− 14.3 (− 28.3 to 
− 0.3)*; d = 0.7 
− 11.7 (− 22.2 to 
















− 11.8 (− 24.9 to 1.3) − 11.4 (− 17.0 to 
− 5.8)***; d = 0.6 













− 9.4 (− 19.8 to 1.0) − 9.8 (− 18.3 to − 1.3)*; 
































− 30.7 (− 50.7 to 
− 10.6)**; d = 0.8 
− 24.0 (− 43.4 to 
− 4.6)*; d = 0.6 













− 7.9 (− 16.5 to 0.7) − 10.5 (− 19.5 to 
− 1.4)*; d = 0.4 
CI indicates confidence interval; PG: placebo control group; AG: articulatory group. SF-36: Short Form-36 Health Survey. QoL: Quality of Life. T1: Pre-treatment; T2: 
Post-treatment: T3: Follow-up; *: p < 0.05; **: p < 0.01; ***: p < 0.001; d: Cohen’s effect size (only for the significant comparisons). 
Fig. 2. Bars represent mean and standard deviation of the percentage of 
decrease in medication intake in the two groups at T2 and T3, and comparisons 
between groups. PG: placebo control group; AG: articulatory group; T2: Post- 
treatment; T3: Follow-up; **: p < 0.01; ***: p < 0.001. 
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perceived change after treatment in patients with migraine, these being 
essential aspects associated with this pathology (Diener et al., 2019; 
Falsiroli-Maistrello et al., 2019). 
Our results showed that pain intensity was reduced in AG individuals 
by 13.0% at T2 and 11.9% at T3. This could be because the joint 
mobilization techniques used in the AG may trigger systemic neuro-
physiological responses in the peripheral and central nervous system 
that lead to pain inhibition (Bialosky et al., 2009, 2018; Schmid et al., 
2008; Voogt et al., 2015). In this regard, our results are consistent with a 
previous study showing that the mobilization of cervical segments C0 – 
C3 improved the intensity of migraine pain after one, three and six 
months following intervention, although without significant differences 
with respect the control group (Davidson et al., 2018). The difference in 
study results may be explained by the treatment protocol applied in the 
present study which targets several regions of the spinal column that 
may be involved in patients with migraine (von Piekartz et al., 2007). 
Regarding the frequency of episodes, the AG intervention improved 
this variable, with a reduction of 11.4% at T2 and 16.9% at T3. Even 
greater changes were observed in a study that applied a 3-month 
treatment based on articulatory techniques (40% after treatment, 
30.8% at one-month follow-up, 36.9% after six months, and 32.3% after 
12 months) (Chaibi et al., 2017). These results suggest that a longer 
intervention could be more effective in reducing the frequency. How-
ever, it is interesting to evaluate the effectiveness of short-term treat-
ments, such as the one proposed in this article, related to this variable, 
since long treatments may lead to a higher probability of drop-outs (Jack 
et al., 2010). In fact, a study that assessed the feasibility of mobilization 
of cervical segments C0 – C3 to reduce headache in migraine sufferers 
during four weeks (Davidson et al., 2018) obtained a 25.8% decrease in 
the frequency, a slightly larger change than ours, which may be 
explained by the greater number of sessions, namely, six instead of four. 
In terms of migraine disability, this improved in the AG both at T2 
(12.9%) and at T3 (29.9%), while improvements were significant 
compared to the PG at T3. Furthermore, the between-group minimally 
important difference was achieved at T2 and T3 (Buse et al., 2018). This 
result is important considering that migraine causes disability in those 
affected (GBD 2016, 2017; Baigi and Stewart, 2015). However, the 
possible effects of manual therapy based on articulatory techniques on 
this variable have been scarcely studied among these patients. A pre-
vious study observed that a manual therapy treatment using soft tissue 
and articulatory techniques in the cervical region was effective in 
reducing disability in patients with chronic migraine and associated 
temporomandibular disorders (7.1%), the results being maintained six 
and twelve weeks (13.1% and 20.9% respectively) after the intervention 
(Garrigós-Pedrón et al., 2018). However, such results are not entirely 
comparable to ours, as headaches associated with temporomandibular 
disorders may develop and respond to therapies differently (Headache 
Classification Committee of the International Headache Society (IHS), 
2018). 
Primary headaches have a negative impact on QoL (Abu Bakar et al., 
2016), and manual therapy is considered an effective approach to 
improve QoL in patients with migraine (Falsiroli-Maistrello et al., 2019). 
However, this is the first study to evaluate the influence of a protocol 
based solely on articulatory techniques in these patients. The results 
point to an improvement in the physical, mental and overall QoL of 
27.7%, 27.3% and 27.5 respectively at T2, and 27.5%, 25.1% and 
26.3%, respectively at T3, achieving clinically important difference 
(Perrot and Lantéri-Minet, 2019), which could be partly explained by 
the reduced pain intensity and frequency (Wang et al., 2001). It is not 
surprising that the physical component improved to a greater extent 
than the mental factor, since patients with migraine tend to suffer 
associated mood disorders (Dresler et al., 2019; Seng and Seng, 2016). 
Voigt et al. (2011) evaluated the efficacy of a ten-week manual therapy 
program in patients with migraine, and similar results were reported for 
the physical component (22.3%), while a poorer outcome was noted for 
the mental component (16.8%). However, they did not have a placebo 
group, so the improvements could not be directly attributed to the 
intervention (Diener et al., 2019). 
Another study applied manual therapy combined with therapeutic 
exercise in patients with primary headaches and obtained better results 
than those of the present study (43.9% in the physical QoL and 27.6% in 
the mental QoL after the intervention, and 42.6% and 21.0% respec-
tively, after nine months follow-up) (Uthaikhup et al., 1016). However, 
such study was not migraine-specific and the evidence suggests that QoL 
differs among headache diagnoses (Wang et al., 2001). On the other 
hand, physical exercise may be contraindicated in some patients 
(Headache Classification Committee of the International Headache So-
ciety (IHS), 2018), so the results of this study showing that patients 
improve the physical sphere only through manual therapy are extremely 
interesting. 
A significant improvement in medication intake at T2 (42.5%) and 
T3 (34.4%) was also observed in AG compared to PG, which is essential 
due to the well-documented side effects of the medication (Becker et al., 
2015; Capi et al., 2018), as well as its influence on the chronification of 
migraine (Xu et al., 2020). Gandolfi et al. (2018) observed that manual 
therapy treatment with mobilization techniques of the cervical and 
thoracic joints together with myofascial therapy was effective for 
Fig. 3. Number of participants rating each category of the PGIC scale at T2 (A) 
and T3 (B). PGIC= Patients’ Global Impression of Change; PG: placebo group; 
AG: articulatory group; T2: Post-treatment; T3: Follow-up; **: p < 0.01; ***: p 
< 0.001. 
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reducing by 28.9% the consumption of symptomatic relief medication. 
However, a study including lumbosacral techniques achieved even 
greater improvements (approximately 50%) (Chaibi et al., 2017) similar 
to ours, which may suggest that combining cervicothoracic and 
lumbosacral techniques could be more effective in reducing medication 
intake. 
In connection with perceived change after treatment, 52% of AG 
participants felt that they had much improved or very much improved 
after the treatment and 20% maintained this improvement at T3, i.e., a 
clinically significant improvement was achieved for this variable (Angst 
et al., 2001; Dworkin et al., 2008). Despite its importance in clinical 
trials on migraine (Diener et al., 2019), this variable has not been 
evaluated in previous studies addressing manual therapy based on 
articulatory techniques in migraine, therefore the study results cannot 
be compared with those attained by other authors. 
However, this study has some limitations. Most participants were 
women, although this seems reasonable since migraine is twice as 
prevalent in women than in men (Woldeamanuel and Cowan, 2017). 
Also, given the variety of techniques used, the improvement cannot be 
entirely attributed to just one of them. 
7. Conclusions 
A manual therapy protocol based on articulatory techniques reduces 
pain intensity, frequency of migraine, migraine disability, and medica-
tion intake, while improving QoL in patients with migraine. Further-
more, the results were maintained after one month. 
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Vicente-Herrero, M., Ramírez-́Iñiguez-de-la-Torre, M., Capdevila-García, L., et al., 2013. 
Chronic migraine and work: occupational risks and prevention. Semergen 39 (6), 
316–324. https://doi.org/10.1016/j.semerg.2012.10.006. 
Vilagut, G., Ferrer, M., Rajmil, L., et al., 2005. El Cuestionario de Salud SF-36 español: 
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